Analysts Offer Insights on Healthcare Companies: C4 Therapeutics (CCCC), ACADIA Pharmaceuticals (ACAD) and Disc Medicine (IRON)
C4 Therapeutics Analyst Ratings
C4 Therapeutics: Hold Rating Maintained Amidst Encouraging Drug Progress and Stable Financials
C4 Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: C4 Therapeutics (CCCC), Halozyme (HALO) and Eli Lilly & Co (LLY)
C4 Therapeutics Analyst Ratings
Strong Financials and Promising Drug Pipeline Bolster Buy Rating for C4 Therapeutics
Analysts Offer Insights on Healthcare Companies: C4 Therapeutics (CCCC), Insulet (PODD) and Healthequity (HQY)
Stifel Nicolaus Sticks to Its Buy Rating for C4 Therapeutics (CCCC)
Analysts Conflicted on These Healthcare Names: C4 Therapeutics (CCCC), Eli Lilly & Co (LLY) and Irhythm Technologies (IRTC)
JP Morgan Upgrades C4 Therapeutics to Neutral, Cites Pipeline
C4 Therapeutics Analyst Ratings
C4 Therapeutics: Strategic Partnerships and Clinical Advancements Bolster Buy Rating
C4 Therapeutics: Hold Rating Maintained Amidst Early Data and Collaboration Potential
Stifel Upgrades C4 Therapeutics to Buy, Raises Price Target to $12
C4 Therapeutics Analyst Ratings
Morgan Stanley Upgrades C4 Therapeutics to Equal-Weight, Lowers Price Target to $1
C4 Therapeutics Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Seagen (SGEN), IQVIA Holdings (IQV) and C4 Therapeutics (CCCC)
C4 Therapeutics Analyst Ratings
No Data